Clinical-Grade Human Pluripotent Stem Cells for Cell Therapy: Characterization Strategy

Area of Science:

• Stem cell biology
• Regenerative medicine
• Biotechnology

Background:

• Human pluripotent stem cells (hPSCs) offer transformative potential for treating human diseases.
• The development of clinical-grade hPSCs, including human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs), must adhere to stringent current good manufacturing practices (cGMP) and regulatory standards.
• Ensuring the highest quality and safety is paramount for hPSC applications in human therapies.

Purpose of the Study:

• To address the need for a consensus on characterization methods for human pluripotent stem cells (hPSCs) intended for clinical use.
• To summarize mandatory and informational characterization techniques for establishing clinical-grade hPSC lines.
• To define release criteria essential for the safe and effective clinical application of hPSCs.

Main Methods:

• Review and summarization of established characterization methods for hPSCs.
• Categorization of methods into 'mandatory' and 'for information only' groups.
• Identification of critical release criteria for clinical-grade hPSC lines.

Main Results:

• A comprehensive overview of essential characterization techniques for clinical-grade hPSCs is presented.
• Distinction between mandatory tests and those for informational purposes is clarified.
• Specific release criteria are proposed to ensure the quality and safety of hPSC lines.

Conclusions:

• Standardized characterization and defined release criteria are crucial for the clinical translation of hPSC therapies.
• Implementing these guidelines will facilitate the safe and reliable use of hPSCs in treating human diseases.
• This consensus on hPSC characterization supports the increasing number of clinical trials utilizing these potent cells.